68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
68Ga-PSMA-11 PET/CT for Screening Prior to 177Lu-PSMA-617 Therapy
Sponsor: Mayo Clinic
Listed as NCT05547386, this PHASE3 trial focuses on Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma and remains completed. Sponsored by Mayo Clinic, it has been updated 11 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Aug 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Aug 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Enrolling By Invitation → Completed
-
Jan 2024 — Feb 2024 [monthly]
Enrolling By Invitation PHASE3
▶ Show 6 earlier versions
-
Dec 2023 — Jan 2024 [monthly]
Enrolling By Invitation PHASE3
-
Jul 2023 — Dec 2023 [monthly]
Enrolling By Invitation PHASE3
-
Mar 2023 — Jul 2023 [monthly]
Enrolling By Invitation PHASE3
Phase: None → PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Enrolling By Invitation
-
Nov 2022 — Feb 2023 [monthly]
Enrolling By Invitation
Status: Not Yet Recruiting → Enrolling By Invitation
-
Sep 2022 — Nov 2022 [monthly]
Not Yet Recruiting
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
For direct contact, visit the study record on ClinicalTrials.gov .